



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



PRODUCT INFORMATION




KPT-185

Item No. 26074

CAS Registry No.: 1333151-73-7
Formal Name: 3-[3-[3-methoxy-5-(trifluoromethyl)phenyl]-1H-1,2,4-triazol-1-yl]-2Z-propenoic acid, 1-methylethyl ester

MF: C₁₆H₁₆F₃N₃O₃
FW: 355.3
Purity: ≥98%
UV/Vis.: λ_{max}: 233, 278 nm
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

KPT-185 is supplied as a solid. A stock solution may be made by dissolving the KPT-185 in the solvent of choice, which should be purged with an inert gas. KPT-185 is soluble in the organic solvent DMSO at a concentration of approximately 15 mg/ml.

Description

KPT-185 is an inhibitor of Exportin 1 (XPO1/CRM1) with anticancer activity.^{1,2} It reduces proliferation in a panel of patient-derived acute myeloid leukemia cells (IC₅₀s = 100-500 nM).¹ KPT-185 induces cell cycle arrest in the G₁ phase and apoptosis in MOLT-4 T cell acute lymphoblastic leukemia cells and in a panel of six non-small cell lung cancer (NSCLC) cell lines in a time- and dose-dependent manner.^{2,3}

References

1. Ranganathan, P., Yu, X., Na, C., *et al.* Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. *Blood* **120**(9), 1765-1773 (2012).
2. Etchin, J., Sanda, T., Mansour, M.R., *et al.* KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. *Br. J. Haematol.* **161**(1), 117-127 (2013).
3. Wang, S., Han, X., Wang, J., *et al.* Antitumor effects of a novel chromosome region maintenance 1 (CRM1) inhibitor on non-small cell lung cancer cells in vitro and in mouse tumor xenografts. *PLoS One* **9**(3), e89848 (2014).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/20/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM